Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin

References

• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
   PubMed Web of Science ®Google Scholar
• Antignani A, FitzGerald D. Immunotoxins: the role of the toxin. Toxins. 2013;5(8):1486–1502.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs. 2009;23(1):1–13.
   PubMed Web of Science ®Google Scholar
• Zuppone S, Fabbrini MS, Vago R. Hosts for hostile protein production: the challenge of recombinant immunotoxin expression. Biomedicines. 2019;7(2):38.
   Web of Science ®Google Scholar
• Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009;9(11):1445–1451.
   PubMed Web of Science ®Google Scholar
• Geretti E, Klagsbrun M. Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr. 2007;1(2):56–61.
   PubMed Web of Science ®Google Scholar
• Oh H, Takagi H, Otani A, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA. 2002;99(1):383–388.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Sengupta K, Dhar K, et al. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. Mol Carcinog. 2006;45(11):871–880.
   PubMed Web of Science ®Google Scholar
• West DC, Rees CG, Duchesne L, et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem. 2005;280(14):13457–13464.
   PubMed Web of Science ®Google Scholar
• Glinka Y, Prud’homme GJ. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol. 2008;84(1):302–310.
   PubMed Web of Science ®Google Scholar
• Herzog B, Pellet-Many C, Britton G, et al. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell. 2011;22(15):2766–2776.
   PubMed Web of Science ®Google Scholar
• Gelfand MV, Hagan N, Tata A, et al. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife. 2014;3:e03720.
   PubMed Web of Science ®Google Scholar
• Jubb AM, Strickland LA, Liu SD, et al. Neuropilin-1 expression in cancer and development. J Pathol. 2012;226(1):50–60.
   PubMed Web of Science ®Google Scholar
• Tirand L, Frochot C, Vanderesse R, et al. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Controlled Release. 2006;111(1–2):153–164.
   PubMed Web of Science ®Google Scholar
• Barr MP, Byrne AM, Duffy AM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer. 2005;92(2):328–333.
   PubMed Web of Science ®Google Scholar
• Raskopf E, Vogt A, Standop J, et al. Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma. Z Gastroenterol. 2010;48(1):21–27.
   PubMed Web of Science ®Google Scholar
• Jarvis A, Allerston CK, Jia H, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010;53(5):2215–2226.
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhou J, Wang S, et al. Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation. Exp Ther Med. 2018;16(2):537–546.
   PubMed Web of Science ®Google Scholar
• Naderi S, Roshan R, Ghaderi H, et al. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis. Mol Immunol. 2020;128:56–63.
   PubMed Web of Science ®Google Scholar
• Homayouni V, Ganjalikhani-Hakemi M, Rezaei A, et al. Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). Iranian J Basic Med Sci. 2016;19(11):1201.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Behdani M, Muyldermans S, et al. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. Drug Test Anal. 2020;12(1):92–100.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Muyldermans S, Habibi-Anbouhi M, et al. Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function. Iran J Basic Med Sci. 2018;21(3):260–266.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Pooshang-Bagheri K, Habibi-Anbouhi M, et al. In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies. Iran J Basic Med Sci. 2017;20(5):489–496.
   PubMed Web of Science ®Google Scholar
• Bagheri M, Babaei E, Shahbazzadeh D, et al. Development of a recombinant camelid specific diabody against the heminecrolysin fraction of Hemiscorpius lepturus scorpion. Toxin Reviews. 2017;36(1):7–11.
   Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Behdani M, Habibi-Anbouhi M, et al. Production and characterization of novel camel single domain antibody targeting mouse vascular endothelial growth factor. Monoclon Antib Immunodiagn Immunother. 2016;35(3):167–171.
   PubMedGoogle Scholar
• Kazemi-Lomedasht F, Behdani M, Rahimpour A, et al. Selection and characterization of specific Nanobody against human immunoglobulin G. Monoclon Antib Immunodiagn Immunother. 2015;34(3):201–205.
   PubMedGoogle Scholar
• Alirahimi E, Ashkiyan A, Kazemi-Lomedasht F, et al. Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. Cancer Gene Ther. 2017;24(1):33–37.
   PubMed Web of Science ®Google Scholar
• Ahadi M, Ghasemian H, Behdani M, et al. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. J Immunotoxicol. 2019;16(1):34–42.
   PubMed Web of Science ®Google Scholar
• Roshan R, Naderi S, Behdani M, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol. 2021;129:70–77.
   PubMed Web of Science ®Google Scholar
• Baharlou R, Tajik N, Behdani M, et al. An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacol Immunotoxicol. 2018;40(5):368–374.
   PubMed Web of Science ®Google Scholar
• Karami E, Sabatier J-M, Behdani M, et al. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. J Enzyme Inhib Med Chem. 2020;35(1):1233–1239.
   PubMed Web of Science ®Google Scholar
• Mohseni N, Roshan R, Naderi S, et al. In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies. Iran J Basic Med Sci. 2020;23(10):1335–1339.
   PubMed Web of Science ®Google Scholar
• Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46(8):1323–1332.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010;21(1):21–26.
   PubMed Web of Science ®Google Scholar
• Denkberg G, Lev A, Eisenbach L, et al. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol. 2003;171(5):2197–2207.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol. 2017;8:1442.
   PubMed Web of Science ®Google Scholar
• Khodabakhsh F, Behdani M, Rami A, et al. Single-domain antibodies or nanobodies: a class of next-generation antibodies. Int Rev Immunol. 2018;37(6):316–322.
   PubMed Web of Science ®Google Scholar
• Alirahimi E, Kazemi-Lomedasht F, Shahbazzadeh D, et al. Nanobodies as novel therapeutic agents in envenomation. Biochim Biophys Acta Gen Subj. 2018;1862(12):2955–2965.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Luqman S. Immune-O-Toxins as the magic bullet for therapeutic purposes. Biomed Res Ther. 2015;2(1):169–183.
   Web of Science ®Google Scholar
• Shafiee F, Aucoin MG, Jahanian-Najafabadi A. Targeted diphtheria toxin-based therapy: a review article. Front Microbiol. 2019;10:2340.
   PubMed Web of Science ®Google Scholar
• Shapira A, Benhar I. Toxin-based therapeutic approaches. Toxins. 2010;2(11):2519–2583.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Getting plant toxins to fuse. Leuk Res. 1997;21(10):997–999.
   PubMed Web of Science ®Google Scholar
• Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun. 1991;180(2):545–551.
   PubMed Web of Science ®Google Scholar
• Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15(1):245–250.
   PubMed Web of Science ®Google Scholar
• Arnaoutova I, George J, Kleinman HK, et al. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis. 2009;12(3):267–274.
   PubMed Web of Science ®Google Scholar
• Albini A, Noonan DM, Ferrari N. Molecular pathways for cancer angioprevention. Clin Cancer Res. 2007;13(15):4320–4325.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Kiosses WB, Liu J, et al. Tumor endothelial cell tube formation model for determining anti-angiogenic activity of a tRNA synthetase cytokine. Methods. 2008;44(2):190–195.
   PubMed Web of Science ®Google Scholar
• Kazemi-Lomedasht F, Behdani M, Bagheri KP, et al. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Mol Immunol. 2015;65(1):58–67.
   PubMed Web of Science ®Google Scholar
• Behdani M, Zeinali S, Karimipour M, et al. Development of VEGFR2-specific nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol. 2013;30(2):205–209.
   PubMed Web of Science ®Google Scholar
• Ribatti D. The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental model. Mech Dev. 2016;141:70–77.
   PubMed Web of Science ®Google Scholar